Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 0.21
GLAXF's Cash to Debt is ranked lower than
55% of the 771 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.69 vs. GLAXF: 0.21 )
GLAXF' s 10-Year Cash to Debt Range
Min: 0.02   Max: No Debt
Current: 0.21

Equity to Asset 0.17
GLAXF's Equity to Asset is ranked lower than
56% of the 711 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.61 vs. GLAXF: 0.17 )
GLAXF' s 10-Year Equity to Asset Range
Min: 0.05   Max: 0.4
Current: 0.17

0.05
0.4
Interest Coverage 9.68
GLAXF's Interest Coverage is ranked higher than
53% of the 431 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 124.75 vs. GLAXF: 9.68 )
GLAXF' s 10-Year Interest Coverage Range
Min: 0.81   Max: 28.06
Current: 9.68

0.81
28.06
F-Score: 5
Z-Score: 2.53
M-Score: -2.75
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating margin (%) 26.52
GLAXF's Operating margin (%) is ranked higher than
94% of the 712 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9.93 vs. GLAXF: 26.52 )
GLAXF' s 10-Year Operating margin (%) Range
Min: 1.68   Max: 36.94
Current: 26.52

1.68
36.94
Net-margin (%) 20.51
GLAXF's Net-margin (%) is ranked higher than
93% of the 712 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.07 vs. GLAXF: 20.51 )
GLAXF' s 10-Year Net-margin (%) Range
Min: 5.76   Max: 23.94
Current: 20.51

5.76
23.94
ROE (%) 77.69
GLAXF's ROE (%) is ranked higher than
99% of the 724 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.00 vs. GLAXF: 77.69 )
GLAXF' s 10-Year ROE (%) Range
Min: 18.39   Max: 173.51
Current: 77.69

18.39
173.51
ROA (%) 12.92
GLAXF's ROA (%) is ranked higher than
96% of the 746 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.87 vs. GLAXF: 12.92 )
GLAXF' s 10-Year ROA (%) Range
Min: 3.87   Max: 27.12
Current: 12.92

3.87
27.12
ROC (Joel Greenblatt) (%) 79.22
GLAXF's ROC (Joel Greenblatt) (%) is ranked higher than
97% of the 740 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 15.90 vs. GLAXF: 79.22 )
GLAXF' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 5.07   Max: 93.68
Current: 79.22

5.07
93.68
Revenue Growth (%) -0.90
GLAXF's Revenue Growth (%) is ranked higher than
59% of the 626 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.10 vs. GLAXF: -0.90 )
GLAXF' s 10-Year Revenue Growth (%) Range
Min: -1.5   Max: 91
Current: -0.9

-1.5
91
EBITDA Growth (%) 17.30
GLAXF's EBITDA Growth (%) is ranked higher than
81% of the 592 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.60 vs. GLAXF: 17.30 )
GLAXF' s 10-Year EBITDA Growth (%) Range
Min: -11.8   Max: 85.9
Current: 17.3

-11.8
85.9
EPS Growth (%) 51.40
GLAXF's EPS Growth (%) is ranked higher than
94% of the 593 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.40 vs. GLAXF: 51.40 )
GLAXF' s 10-Year EPS Growth (%) Range
Min: -30.2   Max: 93.9
Current: 51.4

-30.2
93.9
» GLAXF's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Insider Trades

Latest Guru Trades with GLAXF



No Insider Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 14.50
GLAXF's P/E(ttm) is ranked higher than
93% of the 806 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 40.50 vs. GLAXF: 14.50 )
GLAXF' s 10-Year P/E(ttm) Range
Min: 10.16   Max: 40.41
Current: 14.5

10.16
40.41
P/B 11.20
GLAXF's P/B is ranked higher than
50% of the 806 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.20 vs. GLAXF: 11.20 )
GLAXF' s 10-Year P/B Range
Min: 5.48   Max: 14.06
Current: 11.2

5.48
14.06
P/S 2.90
GLAXF's P/S is ranked higher than
73% of the 806 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.57 vs. GLAXF: 2.90 )
GLAXF' s 10-Year P/S Range
Min: 1.94   Max: 4.9
Current: 2.9

1.94
4.9
PFCF 14.40
GLAXF's PFCF is ranked higher than
94% of the 806 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9999.00 vs. GLAXF: 14.40 )
GLAXF' s 10-Year PFCF Range
Min: 8.21   Max: 41.33
Current: 14.4

8.21
41.33
EV-to-EBIT 13.84
GLAXF's EV-to-EBIT is ranked higher than
90% of the 806 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 32.97 vs. GLAXF: 13.84 )
GLAXF' s 10-Year EV-to-EBIT Range
Min: 7.7   Max: 240.2
Current: 13.84

7.7
240.2
PEG 6.10
GLAXF's PEG is ranked higher than
79% of the 806 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 356.67 vs. GLAXF: 6.10 )
GLAXF' s 10-Year PEG Range
Min: 0.23   Max: 99.36
Current: 6.1

0.23
99.36
Shiller P/E 16.60
GLAXF's Shiller P/E is ranked higher than
94% of the 806 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9999.00 vs. GLAXF: 16.60 )
GLAXF' s 10-Year Shiller P/E Range
Min: 10.82   Max: 21.72
Current: 16.6

10.82
21.72
Current Ratio 1.14
GLAXF's Current Ratio is ranked higher than
50% of the 759 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.31 vs. GLAXF: 1.14 )
GLAXF' s 10-Year Current Ratio Range
Min: 0.97   Max: 1.78
Current: 1.14

0.97
1.78
Quick Ratio 0.78
GLAXF's Quick Ratio is ranked lower than
52% of the 759 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.67 vs. GLAXF: 0.78 )
GLAXF' s 10-Year Quick Ratio Range
Min: 0.68   Max: 1.42
Current: 0.78

0.68
1.42

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 5.00
GLAXF's Dividend Yield is ranked higher than
98% of the 452 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.37 vs. GLAXF: 5.00 )
GLAXF' s 10-Year Dividend Yield Range
Min: 2.72   Max: 5.69
Current: 5

2.72
5.69
Dividend Payout 1.64
GLAXF's Dividend Payout is ranked higher than
90% of the 806 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9999.00 vs. GLAXF: 1.64 )
GLAXF' s 10-Year Dividend Payout Range
Min: 0.38   Max: 4.69
Current: 1.64

0.38
4.69
Dividend growth (3y) 6.40
GLAXF's Dividend growth (3y) is ranked higher than
81% of the 317 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.50 vs. GLAXF: 6.40 )
GLAXF' s 10-Year Dividend growth (3y) Range
Min: -12.6   Max: 20.8
Current: 6.4

-12.6
20.8
Yield on cost (5-Year) 6.85
GLAXF's Yield on cost (5-Year) is ranked higher than
97% of the 459 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.40 vs. GLAXF: 6.85 )
GLAXF' s 10-Year Yield on cost (5-Year) Range
Min: 3.73   Max: 7.8
Current: 6.85

3.73
7.8
Share Buyback Rate 1.40
GLAXF's Share Buyback Rate is ranked higher than
89% of the 554 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: -1.50 vs. GLAXF: 1.40 )
GLAXF' s 10-Year Share Buyback Rate Range
Min: 51.8   Max: -20
Current: 1.4

Valuation & Return

vs
industry
vs
history
Price/DCF (Projected) 1.60
GLAXF's Price/DCF (Projected) is ranked higher than
92% of the 806 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9999.00 vs. GLAXF: 1.60 )
GLAXF' s 10-Year Price/DCF (Projected) Range
Min: 0.82   Max: 4.41
Current: 1.6

0.82
4.41
Price/Median PS Value 1.10
GLAXF's Price/Median PS Value is ranked higher than
79% of the 806 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.23 vs. GLAXF: 1.10 )
GLAXF' s 10-Year Price/Median PS Value Range
Min: 0.68   Max: 2.56
Current: 1.1

0.68
2.56
Earnings Yield (Greenblatt) 7.40
GLAXF's Earnings Yield (Greenblatt) is ranked higher than
83% of the 621 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.00 vs. GLAXF: 7.40 )
GLAXF' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.4   Max: 12.9
Current: 7.4

0.4
12.9
Forward Rate of Return (Yacktman) 5.67
GLAXF's Forward Rate of Return (Yacktman) is ranked higher than
77% of the 622 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.99 vs. GLAXF: 5.67 )
GLAXF' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 2.2   Max: 67.4
Current: 5.67

2.2
67.4

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major
Compare:JNJ, PFE, RHHBY, NVS, ABT » details
Traded in other countries:GSK.UK, GSK.USA, GS7A.Germany, GS7.Germany
GlaxoSmithKline PLC incorporated in United Kingdom. The Company creates, discoveres, develops, manufactures and markets pharmaceutical products including vaccines, over-the-counter (OTC) medicines and health-related consumer products. The Company's principal pharmaceutical products include medicines in the following therapeutic areas: respiratory, anti-virals including HIV, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, oncology and emesis, vaccines and dermatologicals. The Company operates in two industry segments: Pharmaceuticals and Consumer Healthcare. The Company's pharmaceutical products include treatments for asthma, HIV/AIDS, malaria, depression, migraine, diabetes, heart failure, digestive conditions and cancer. The Company markets over 25 vaccines worldwide to prevent potentially life-threatening or crippling illnesses such as hepatitis A, hepatitis B, diphtheria, tetanus, whooping cough, measles, mumps, rubella, polio, typhoid, influenza and bacterial meningitis. The Company produces medicines that treat six major disease areas - asthma, virus control, infections, mental health, diabetes and digestive conditions. In addition, it is developing new treatments for cancer. The Company's portfolio comprises three main categories: OTC medicines, Oral healthcare and Nutritional healthcare. OTC medicines- alli is the first licensed weight loss medicine to be available without a prescription, launched in the USA in 2007. Oral healthcare- Aquafresh, a range of toothpastes, toothbrushes and mouthwashes; Sensodyne, a range of toothpastes and toothbrushes, including Pronamel to protect from acid erosion; Biotene; Polident, PoliGrip and Corega, the denture care cleansers and adhesives; and Other brands include Odol, Macleans and Dr Best. Nutritional healthcare- Lucozade is a range of energy and sports drinks; Horlicks, a range of milk-based malted food and chocolate drinks; and Ribena, a blackcurrant juice-based drink. The Company has operations in USA, Europe, Asia Pacific, Japan and Canada.
» More Articles for OTCPK:GLAXF

Headlines

Articles On GuruFocus.com
Highest Yielding Stocks Widely Held By The Gurus Jul 01 2014 
Diamond Hill Capital Comments on GlaxoSmithKline PLC Jun 26 2014 
Major British Companies Lead Top Guru-Held UK and Ireland Stocks Jun 10 2014 
Can Pfizer Make Up Its Loss? May 09 2014 
Auxier Asset Management's Auxier Report - First Quarter 2014 May 06 2014 
Weekly 52-Week Highs Highlight: AV, XEL, OKE, GSK Apr 28 2014 
These Three Pharmaceutical Companies Shake The Market With Their Deal Apr 27 2014 
GlaxoSmithKline Finally Received Approval from FDA for Its Diabetes Drug Tanzeum (Albiglutide) Apr 19 2014 
Why Buy-and-Hold-Forever Buffett’s Company Just Sold Two Stocks Feb 27 2014 
10 British Stocks to Consider Feb 20 2014 

More From Other Websites
UK boards urged to take control of ethical values Jul 20 2014
China to hold public trial of couple who worked for GSK Jul 17 2014
AbbVie set to unveil £31bn Shire takeover Jul 17 2014
China backtracks on secret trial for GSK private investigator Jul 17 2014
China to hold public trial of foreign couple who worked for GSK Jul 17 2014
FTSE slips from one-week high as sanctions tighten on Russia Jul 17 2014
Novartis maintains forecasts despite weak quarter Jul 17 2014
GSK confirms it fired staff for corruption in China in 2001 Jul 17 2014
Foreign companies are easy prey in China Jul 17 2014
GSK admits to 2001 China bribery scandal Jul 16 2014
GlaxoSmithKline recalls painkiller in Puerto Rico Jul 14 2014
GSK Bribery Probe: UK Investigator Charged Jul 14 2014
China charges GSK-linked investigators for illegally obtaining private information Jul 14 2014
China confirms trial of GSK investigators Jul 13 2014
China charges GSK-linked investigators for illegally obtaining private information Jul 13 2014
China beats up on Apple for location-tracking apps Jul 11 2014
Sanofi dengue vaccine promising but questions remain Jul 11 2014
The FTSE 100 Will Surge Above 7,000 By The End Of The Year! Jul 09 2014
The Hong Kong arms of the Big Four have got the rule of law wrong Jul 09 2014
Neil Woodford Still Loves Astrazeneca plc And GlaxoSmithKline plc Jul 08 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Email Hide